Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol anesthesia and postoperative inflammatory response after laparoscopic hepatectomy
ChiCTR2300072885Phase 4Not yet recruiting
- Sponsor
- Guangzhou Panyu District Central Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in hepatic disease and hepatic neoplasm (3 arms), sponsored by Guangzhou Panyu District Central Hospital. Primary endpoints: C-reactive protein (CRP), Procalcitonin (PCT) and 4 more. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
hepatic diseasehepatic neoplasm
Beyond the preview
Go deeper on ChiCTR2300072885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072885.